Mitochondria, Insulin Resistance, and the Future of Diabetes Treatment

In this episode, we meet Prof Gerald Shulman, recipient of this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, whose pioneering research has reshaped our understanding of insulin resistance and its role in type 2 diabetes and beyond. Prof. Shulman shares insights from over four decades of research into how ectopic lipid accumulation disrupts insulin signalling, leading to diabetes, fatty liver disease, cardiovascular complications, cancers, and Alzheimer’s disease. He explains how his discoveries - from the role of diacylglycerols to innovative mitochondrial-targeted therapies now in clinical trials - could mark a paradigm shift in the treatment of insulin resistance. Join us for this inspiring conversation on the future of metabolic medicine and the exciting prospect of treating insulin resistance as a central target for preventing chronic disease.

There are no comments yet.

Please log in to write the first comment.